Clinical Trial Update: An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating HCB301, an engineered Sirpα fusion with anti-PD-L1 and TGF-β activity, in patients with selected advanced solid tumors and r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• HCB301

Snippet

Sponsor: FBD Biologics Limited | Conditions: Advanced Solid Tumor, Refractory Hodgkin Lymphoma | Phase 1 | Status: RECRUITING